• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 229

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy and What Comes Next

The Psychedelic News Feed: December 1 – 7, 2025

The Psychedelic News Feed: November 24 – 30, 2025

Pα+ Psychedelic Bulletin #215: FDA’s Move to Single-Trial Approvals; Freedom to Heal Act Looks to Unlock Right to Try Psychedelics; Compass Clarifies Q1 Readout...

Filament Health Successfully Completes Industry-first Export of Natural GMP Psychedelics to...

Scientists Isolate Two New Compounds from Toad Venom

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to...

Mindset Pharma Announces Preclinical Results Demonstrating Extended Duration of Action in...

MYND Life Sciences Announces $3 Million Convertible Debenture Unit Offering

MINDCURE Reaches Milestone, Releasing First of its Kind Mental Health Digital...

Silo Pharma Advances Psychedelic Patent Portfolio

PharmaDrug Announces Clinical Research Collaboration with The Johns Hopkins University to...

Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon...

Microdosing LSD Makes Me a Better Mom

1...228229230...304Page 229 of 304

EDITOR PICKS

The Psychedelic Practitioner Issue 2: Preparation

Evidence and Experience: Samuel Wilkinson on the State of (Es)ketamine Therapy...

The Psychedelic News Feed: December 1 – 7, 2025

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©